Robert Dunn, MD, PhD, serves as the Chief Scientific Officer at Clinilabs. With two decades of experience in clinical development and neuroscience research, he is a notable figure in the field of central nervous system (CNS) research. Bob has directed and designed clinical studies across various phases, from Phase I to Phase IV, and has collaborated with key opinion leaders, vendors, and interdisciplinary teams on numerous neuroscience projects. His expertise encompasses psychiatric conditions such as unipolar depression, schizophrenia, bipolar depression, anxiety, and autism.

Previously, Bob held positions at Pfizer, Forest Research Institute, and Forum Pharmaceuticals, and he also served as an Assistant Professor at Harvard Medical School. He earned his MD and PhD in Pharmacology and Physiology from the University of Chicago Pritzker School of Medicine. Bob’s ultimate goal is to provide innovative and effective solutions for individuals suffering from psychiatric and neurological disorders.

< Back to Leadership Team